EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial

Zhiyuan Xu, Can Hu, Litao Yang, Pengfei Yu, Yanqiang Zhang, Jiahui Chen, Guoliang Zheng, Xiaodong Chen, Tao Zhang, Weiyang He, Xiangyu Meng, Panpan Yu und 14 weitere

Cancer Cell · 2026

DOI: 10.1016/j.ccell.2026.06.015 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026. Verfasst von Zhiyuan Xu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, Medical Science and Technology Project of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedAgedProspective StudiesPathologic Complete ResponseAdultBiomarkers, Tumor

Stichwörter der Autor:innen

gastric cancerperioperative immunotherapytsMHC-II

Substanzen

Antibodies, Monoclonal, HumanizedBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; Key Laboratory of Prevention, Diagnosis and Therapy of Upper…
  • Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
  • Department of Gastric Surgery, Liaoning Cancer Hospital, Shenyang, Liaoning, China.
  • Department of Gastric Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
  • Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.

Förderung

  • Zhejiang Province Natural Science Foundation
  • Medical Science and Technology Project of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Z., Hu, C., Yang, L., Yu, P., Zhang, Y., Chen, J., Zheng, G., Chen, X., Zhang, T., He, W., Meng, X., Yu, P., Du, Y., Liu, X., Liu, Y., Wang, Y., Wu, X., Pan, S., Zhang, R., …, & Cheng, X. (2026). Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.06.015

Vancouver

Xu Z, Hu C, Yang L, Yu P, Zhang Y, Chen J, et al. Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.06.015

BibTeX
@article{Xu2026,
  author = {Xu, Zhiyuan and Hu, Can and Yang, Litao and Yu, Pengfei and Zhang, Yanqiang and Chen, Jiahui and Zheng, Guoliang and Chen, Xiaodong and Zhang, Tao and He, Weiyang and Meng, Xiangyu and Yu, Panpan and Du, Yian and Liu, Xiaowen and Liu, Youdong and Wang, Yongxiang and Wu, Xiaoxiao and Pan, Siwei and Zhang, Ruolan and Zhang, Shengjie and Xiong, Zhirong and Sun, Wei and Dong, Chuanxin and Liu, Jiajun and Wu, Yuexian and Cheng, Xiangdong},
  title = {Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2026.06.015}
}
Kostenlos starten →